Premium
Serum soluble lymphocyte activation gene‐3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study
Author(s) -
Cui Shishuang,
Du JuanJuan,
Liu ShiHua,
Meng Jie,
Lin YiQi,
Li Gen,
He YiXi,
Zhang PingChen,
Chen Shengdi,
Wang Gang
Publication year - 2019
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.27569
Subject(s) - biomarker , parkinson's disease , medicine , neurodegeneration , disease , logistic regression , pathogenesis , pathological , chemistry , biochemistry
Objective Lymphocyte activation gene‐3 (LAG‐3) could mediate pathological α‐synuclein transmission in neurodegeneration and may be involved in the pathogenesis of Parkinson's disease (PD). The aim of the present study was to explore soluble LAG‐3 (sLAG‐3) as a potential diagnostic biomarker for PD. Methods Serum sLAG‐3 concentrations were measured by a quantitative ELISA for patients with PD, essential tremor (ET) and age‐ and sex‐matched controls. The relationships between sLAG‐3 and clinical phenotype were assessed via correlation analysis and logistic regression. Results Serum sLAG‐3 levels in patients with PD were significantly higher than those in ET patients and age‐ and sex‐matched controls. The area under the curve of serum sLAG‐3 in differentiating PD from age‐ and sex‐matched controls was 0.82. Serum sLAG‐3 was associated with non‐motor symptoms and excessive daytime sleep. Conclusion sLAG‐3 is a candidate novel biomarker for PD. © 2018 International Parkinson and Movement Disorder Society